Intra‑Articular Corticosteroid Injection Guidelines for Adults

Injection Frequency and Cumulative Safety

• Limit repeat glucocorticoid injections in the same joint to no more than 3–4 times per year to reduce risk of cartilage damage and other cumulative adverse effects; this recommendation is based on expert consensus (low‑level evidence) rather than high‑quality trials. 1

Cartilage Effects

• Conflicting evidence exists regarding cartilage preservation: one randomized controlled trial (high‑level evidence) found no detrimental effect on cartilage volume when injections were given every 3 months for 2 years, whereas another RCT reported greater cartilage volume loss under the same schedule. 2

Diabetes Management

• Patients with diabetes should be counseled that intra‑articular corticosteroids can cause transient hyperglycemia, typically during days 1–3 after injection; they should monitor glucose levels during this period. No cases of severe hyperglycemic emergencies (e.g., ketoacidosis) have been reported. This guidance derives from observational cohort data (moderate evidence). 2

Prosthetic Joint Considerations

• Routine glucocorticoid injections should be avoided in prosthetic joints because of infection risk.
• In total knee prostheses, the infection rate after injection is approximately 0.6 % (1 in 625 injections).
• If an injection is deemed necessary, strict screening for prosthetic infection by an orthopedic surgeon is required. These points are supported by registry‑based observational studies (moderate evidence). 1

Timing Relative to Joint Arthroplasty

• Do not perform intra‑articular corticosteroid injections within 3 months before a planned total joint arthroplasty.
• Injections administered 0–3 months pre‑operatively are associated with a higher prosthetic infection rate (0.5–1.0 %) compared with injections given >3 months before surgery, although the absolute risk increase is modest. Evidence comes from retrospective cohort analyses (moderate evidence). 4

Post‑Injection Activity Recommendations

• Patients should avoid overuse of the injected joint for at least 24 hours after the procedure.
• Immobilization is discouraged; normal activity is preferred over bed rest, splinting, or bandaging, as 24–48 hour immobilization provides no additional benefit. These recommendations are based on prospective comparative studies (moderate evidence). 1

Expected Clinical Outcomes

• Intra‑articular corticosteroid injections provide short‑term pain relief lasting from a few weeks up to several months.
• Evidence for long‑term efficacy is limited and mixed, with studies showing variable durability of pain and functional improvements. This summary reflects aggregate data from multiple trials and observational studies (moderate evidence). 2